GARPR Online Reporting Tool

Uganda - 2015

I Narrative Report and Cover Sheet

1) Which institutions/entities were responsible for filling out the indicator forms?

a) NAC or equivalent: Yes

b) NAP: No

c) Others: No

If Others, please specify:

2) With inputs from

Ministry of Education: Yes

Ministry of Health: Yes

Ministry of Labour: Yes

Ministry of Foreign Affairs: No

Other Ministry: No

If Other Ministry, please specify:

Civil society organizations: Yes

People living with HIV: Yes

Private sector: Yes

United Nations organizations: Yes

Bilateral organizations: Yes

International NGOs: Yes

Others: No

If Others, please specify:

3) Was the report discussed in a large forum?: Yes

4) Are the survey results stored centrally?: Yes

5) Are data available for public consultation?: Yes

6) Who is the person responsible for submission of the report?

Name(s) / title(s): : Dr. Christine JD. Ondoa

Address(es): : Uganda AIDS Commission Plot 1-3 Salim Bey Road, Ntinda P.O.Box 10779, Kampala Tel: + 256 414 288065 www. aidsugnada.org

Email(s):: jcondoa@hotmail.com

Telephone(s): : + 256414288065

1.1 Young People: knowledge about HIV prevention

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Other General Population Based Survey

Other measurement tool / source: LQAS- 2015 conducted in 66 districts

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns:: Most of LQAS indicators are proxy and only data covered 66 districts out of 112 in the country

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents: 6919

Correct answer to all five questions

	All (15-24)	All Males (15-24)	Males (15-19)	Males (20-24)	All Females (15-24)	Females (15-19)	Females (20-24)
Percentage (%) : Percentage of respondents aged 15-24 years who gave the correct answer to all five questions	36.8	39.4	36.4	42.7	34.6	32.4	37.7
Numerator : Number of respondents aged 15-24 years who gave the correct answer to all five questions	2232	1108	541	567	1124	620	504
Denominator : Number of all respondents aged 15-24	6064	2814	1485	1328	3249	1913	1336

Correct answer to question 1 "Can the risk of HIV transmission be reduced by having sex with only one uninfected partner who has no other partners?"

	All (15-24)	All Males (15-24)	Males (15-19)	Males (20-24)	All Females (15-24)	Females (15-19)	Females (20-24)
Percentage (%) : Percentage of respondents who gave a correct answer to question 1	47.99	48.01	40.07	56.85	47.98	41.30	57.49
Numerator : Numerator Number of respondents/population who gave correct answer to question 1	2910	1351	595	755	1559	790	768
Denominator : Number of all respondents age 15-24	6064	2814	1485	1328	3249	1913	1336

Correct answer to question 2 "Can a person reduce the risk fo getting HIV by using a condom every time they have sex?"

	All (15-24)	All Males (15-24)	Males (15-19)	Males (20-24)	All Females (15-24)	Females (15-19)	Females (20-24)
Percentage (%) : Percentage of respondents who gave a correct answer to question 2	77	81.3	77.4	85.7	73.2	68.5	80
Numerator : Number of respondents/population who gave correct answer to question 2	4667	2288	1149	1138	2379	1310	1069
Denominator : Number of all respondents age 15-24	6064	2814	1485	1328	3249	1913	1336

Correct answer to question 3 "Can a healthy-looking person have HIV" ?

	All (15-24)	All Males (15-24)	Males (15-19)	Males (20-24)	All Females (15-24)	Females (15-19)	Females (20-24)
Percentage (%) : Percentage of respondents who gave a correct answer to question 3							
Numerator : Number of respondents/population who gave correct answer to question 3							
Denominator : Number of all respondents age 15-24							

Correct answer to question 4 "Can a person get HIV from mosquito bites?" (or country specific question)

	All (15-24)	All Males (15-24)	Males (15-19)	Males (20-24)	All Females (15-24)	Females (15-19)	Females (20-24)
Percentage (%) : Percentage of respondents who gave a correct answer to question 4	65.820	66.513	65.185	68.00	65.220	64.611	66.093
Numerator : Number of respondents/population who gave correct answer to question 4	3990	1871	968	903	2119	1236	883
Denominator : Number of all respondents age 15-24	6062	2813	1485	1328	3249	1913	1336

Correct answer to question 5 "Can a person get HIV by sharing food with someone who is infected?" (or country specific question)

	All (15-24)	All Males (15-24)	Males (15-19)	Males (20-24)	All Females (15-24)	Females (15-19)	Females (20-24)
Percentage (%) : Percentage of respondents who gave a correct answer to question 5	89.9	89.9	89.4	90.6	89.8	89.3	90.6
Numerator : Number of respondents/population who gave correct answer to question 5	5451	2531	1327	1203	2920	1709	1210
Denominator : Number of all respondents age 15-24	6064	2814	1485	1328	3250	1913	1336

1.2 Young people: sex before the age of 15

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Other

Other measurement tool / source: LQAS 2015

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents: 6919

	All (15-24)	All Males (15-24)	Males (15-19)	Males (20-24)	All Females (15-24)	Females (15-19)	Females (20-24)
Percentage (%) : Percentage of young women and men aged 15-24 who have had sexual intercourse before the age of 15	6.2	8.4	10.8	5.8	4.3	5.5	2.4
Numerator : Number of respondents (aged 15-24 years) who report the age at which they first had sexual intercourse as under 15	431	276	184	92	155	119	36
Denominator : Number of all respondents aged 15-24	6917	3286	1709	1577	3631	2150	1481

1.3 Multiple sexual partnerships

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Other

Other measurement tool / source: 2015 LQAS

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents: 13953

	All (15-49)	Males (15-49)	Males (15-19)	Males (20-24)	Males (25-49)	Females (15-49)	Females (15-19)	Females (20-24)	Females (25-49)
Percentage (%) : Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months	11.6	17.1	17.1	17.7	16.9	6.7	9.9	6.4	6.1
Numerator : Number of respondents aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months	1623	1135	96	253	786	488	100	122	266
Denominator : Number of all respondents aged 15-49	13953	6654	563	1430	4660	7299	1011	1916	4372

1.4 Condom use at last sex among people with multiple sexual partnerships

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Other Behavioural Surveillance Survey

Other measurement tool / source: LQAS

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents: 13953

	All (15-49)	Males (15-49)	Males (15-19)	Males (20-24)	Males (25-49)	Females (15-49)	Females (15-19)	Females (20-24)	Females (25-49)
Percentage (%) : Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse	55.6	59.8	67.0	69.6	54.7	48.7	65.6	59.8	36.2
Numerator : Number of respondents (aged 15-49) who reported having had more than one sexual partner in the past 12 months who also reported that a condom was used the last time they had sex	1690	1133	140	330	663	557	145	198	214
Denominator : Number of respondents (15-49) who reported having had more than one sexual partner in the last 12 months	3037	1894	209	474	1211	1143	221	331	591

1.5 People living with HIV who know their status

I. Case-based reporting (Data reported through a system that reports individual level data on every person diagnosed with HIV to a national public health entity.)

Are data available?: No

Source:

Year when case-based reporting started:

	All ages	Males (all ages)	Males (0-14)	Males (15-49)	Males (50+)	Females (all ages)	Females (0-14)	Females (15-49)	Females (50+)
Percentage (%) : Percentage of people living with HIV who know their status									
A : Cumulative number of people living with HIV diagnosed									
B : Cumulative number of all deaths among HIV infected people									
Numerator (A-B) : Number of people who are alive and know their status									
Denominator : Estimated number of people living with HIV (e.g. from Spectrum)									

Take denominator from the final Spectrum file: No

II. Survey-based reporting (Data collected through nationally representative survey on HIV status or testing status)

a) Direct measure: Survey respondents are asked directly whether they know their HIV status (not whether they have been tested):

Are data available?: No

Source:

Year :

	All adults	Male adults	Female adults
Age range (e.g. 15+, 15-49, etc.)			
Percentage (%) : Percentage of people living with HIV who know their status			
Numerator : Respondents living with HIV who report having been diagnosed			
Denominator : Respondents living with HIV			

b) Indirect measure: The estimated percent of people living with HIV that know their status estimated from survey data on when people were last tested for HIV

Are data available?: Yes

b.i) Percent of respondents who have never been tested for HIV

Source: 2011 AIS

Year: 2011

	All adults	Male adults	Female adults
Age range (e.g. 15+, 15-64)	15-59	15-59	15-59
Percentage (upper bound)	69.17	57.73	76.52
Numerator : Respondents living with HIV ever previously tested for HIV and received their last test results	1030	336	694
Denominator : Respondents living with HIV	1489	582	907

b.ii) Percent of people living with HIV who know status because they are receiving ART (refer to indicator 4.1)

Source: HMIS

Year: 2015

	All (15+)	Males (15+)	Females (15+)
Percentage (lower bound 1)			
Numerator : Number of people living with HIV receiving ART	774902	258291	516611
Denominator : Estimated number of people living with HIV (e.g. from Spectrum)			

Take denominator from the final Spectrum file: Yes

b.iii) Percent of people living with HIV who know status because they are receiving HIV care (refer to indicator 4.3)

Source: HMIS

Year: 2015

	All (15+)	Males (15+)	Females (15+)
Percentage (lower bound 2)			
Numerator : Number of people living with HIV in care	880872	293613	587259
Denominator : Estimated number of people living with HIV (e.g. from Spectrum)			

Take denominator from the final Spectrum file: Yes

b) Results of indirect survey measure: the estimated range of people living with HIV who know their status

	All adults	Male adults	Female adults
Range : Percentage of people living with HIV who know their status			

Additional information related to entered data. e.g. reference to primary data source, methodological concerns:

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Number of people who are alive and know their status	Estimated number of people living with HIV	Source of estimate

1.6 HIV prevalence from antenatal clinics by age group

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Antenatal care clinic registers

Other measurement tool / source:

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:: Age specific ANC testing data is from July 2015 for only 687,190 out of the 1,735,399 Mothers. We have only 3 age categories. Numbers under 25-29 has all women pregnant above 25 years.

	All (15-49)	15-19	20-24	25-29	30-34	35-39	40-44	45-49
Prevalence (%) : HIV prevalence among women attending antenatal clinics in the general population	6.1	1.9	2.7	2.7				
Numerator : Number of pregnant women who tested HIV positive (including those who already know their HIV positive status) who attended antenatal clinics	105396	2652	6501	8234				
Denominator : Number of women tested for HIV at antenatal clinics (including those who already know their HIV positive status).	1735399	143060	214548	302582				

Sub-national data

Please enter the breakdown per region below. [Add as many as needed]

Sub-national region	Numerator All(15-49)	Denominator All(15-49)	Numerator 15-19	Denominator 15-19	Numerator 20-24	Denominator 20-24	Numerator 25-29	Denominator 25-29	Numerator 30-34	Denominator 30-34	Numerator 35-39	Denominator 35-39	Numerator 40-44	Denominator 40-44	Numerator 45-49	Denominator 45-49

Alternatively, you may download this template, fill in the columns, and upload using the "Add File" button.

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Prevalence (%)	Numerator	Denominator

1.20 HIV incidence rate

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Indirect measurement (e.g. Spectrum or AEM)

Other measurement tool / source:

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Take data from the final Spectrum file: Yes

by sex and by age

	15-49	Males (15-49)	Females (15-49)	15-24	Males (15-24)	Females (15-24)	0-14	All
Incidence : Number of new HIV infections in the reporting period per 1000 uninfected population								
Numerator : Number of new infections during the reporting period multiplied by 1000								
Denominator : Total number of uninfected population (or person-years exposed)								

Sub-national data

Please enter the breakdown per region below. [Add as many as needed]

Sub-national region	Incidence per 1000 (adults 15-49*)	Incidence per 1000 (males 15-49*)	Incidence per 1000 (females 15-49*)	Numerator (adults 15-49*)	Numerator (males 15-49*)	Numerator (females 15-49*)	Denominator (adults 15-49*)	Denominator (males 15-49*)	Denominator (females 15-49*)	*Age range (if 15-49 is not available)

Alternatively, you may download this template, fill in the columns, and upload using the "Add File" button.

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Incidence per 1000 (adults 15-49*)	Incidence per 1000 (males 15-49*)	Incidence per 1000 (females 15-49*)	Numerator (adults 15-49*)	Numerator (males 15-49*)	Numerator (females 15-49*)	Denominator (adults 15-49*)	Denominator (males 15-49*)	Denominator (females 15-49*)	*Age range (if 15-49 is not available)

1.22 Male circumcision, prevalence

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents:

	All (15-49)	15-19	20-24	25-49	Formal healthcare system	Traditional practitioner
Percentage (%) : Percentage of men 15-49 that are circumcised						
Numerator : Number of male respondents aged 15–49 who report they are circumcised						
Denominator : Number of all male respondents aged 15–49 years						

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Percentage (%)	Numerator	Denominator

1.23 Annual number of men voluntarily circumcised

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Health information system

Other measurement tool / source: DHIS2

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::
Data is not dis-aggregated by age group, only

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents:

	Total	< 1	1-9	10-14	15-19	20-24	25-49	15-49	50+
Numerator : Number of males circumcised during the past 12 months according to national standards	497978								

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Numerator
Kampala	37815
Gulu	7475
Mbarara	14418

2.1 Size estimations for key populations

	Have you estimated the size of key populations? (Yes/No)	If yes, when (year) was the latest estimation?	If yes, what was the estimation?
Sex workers	No		
Men who have sex with men	No		
People who inject drugs	No		
Transgender	No		
Prisoners	No		

Additional information

Sex workers

For which region was the last estimation performed?:

What was the method used to perform the estimation?:

Comments:

City-specific data (sex workers):

City	Year of latest estimation	Method to derive the size estimate	Size estimate

Men who have sex with men

For which region was the last estimation performed?:

What was the method used to perform the estimation?:

Comments :

City-specific data (men who have sex with men):

City	Year of latest estimation	Method to derive the size estimate	Size estimate

People who inject drugs

For which region was the last estimation performed?:

If yes, what was the method used to perform the estimation?:

Comments:

City-specific data (people who inject drugs):

City	Year of latest estimation	Method to derive the size estimate	Size estimate

Transgender people

For which region was the last estimation performed?:

If yes, what was the method used to perform the estimation?:

Comments:

Inmates/detainees

For which region was the last census performed?:

Comments:

a) Sex workers

Is topic relevant?: Yes

Case definition:

Number of sites:

Information about the sites:

Sampling method:

Are the data representative of the entire country?: No

2.2 Sex workers: condom use

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Other (please specify sampling strategy and location)

Other measurement tool / source: MRC have data on female sex workers and not on male sex workers. The percentage of female sex workers is based on data from the Good Health for Women Project in Kampala, an on-going cohort of self-identified women at risk of HIV. In 2014, questionnaires were administered every 3 months. We have used data for women, who in 2014 reported being commercial sex workers and reported having sex with a non-marital partner within the last month, at the last sexual act.

From date: 01/01/2014

To date: 31/12/2014

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents: 1297

	All	Males	Females	Transgender	<25	25+
Percentage (%) : Percentage of sex workers reporting the use of a condom with their most recent client	69.4		69.4		68.2	69.8
Numerator : Number of sex workers who reported that a condom was used with their last client	900		900		238	662
Denominator : Number of sex workers who reported having commercial sex in the past 12 months	1297		1297		349	948

Sub-national data

Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator

Disaggregated by sex

Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]

Site	Males - Numerator	Males - Denominator	Females - Numerator	Females - Denominator	Males (<25) - Numerator	Males (<25) - Denominator	Females (<25) - Numerator	Females (<25) - Denominator

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Year of survey	Sample size	Percentage (%)	Numerator	Denominator

2.3 HIV testing in sex workers

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Other (please specify sampling strategy and location)

Other measurement tool / source: MRC study MRC have data on female sex workers and not on male sex workers. The percentage of female sex workers is based on data from the Good Health for Women Project in Kampala, an on-going cohort of self-identified women at risk of HIV. In 2014, questionnaires were administered every 3 months. We have used data for women, who in 2014 reported being commercial sex workers and reported having sex with a non-marital partner within the last month, at the last sexual act.

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents: 1441

	All	Males	Females	Transgender	<25	25+
Percentage (%) : Percentage of sex workers who received an HIV test in the past 12 months and know their results	100		100		100	100
Numerator : Number of sex workers who have been tested for HIV during the past 12 months and who know their results	1441		1441		380	1061
Denominator : Number of sex workers included in the sample	1441		1441		380	1061

Sub-national data

Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator

Disaggregated by sex

Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]

Site	Males - Numerator	Males - Denominator	Females - Numerator	Females - Denominator	Males (<25) - Numerator	Males (<25) - Denominator	Females (<25) - Numerator	Females (<25) - Denominator

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Year of survey	Sample size	Percentage (%)	Numerator	Denominator

2.4 HIV prevalence in sex workers

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents:

	All	Males	Females	Transgender	<25	25+
Percentage (%) : Percentage of sex workers living with HIV						
Numerator : Number of sex workers who test positive for HIV						
Denominator : Number of sex workers tested for HIV						

Sub-national data

Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator

Disaggregated by sex

Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]

Site	Males - Numerator	Males - Denominator	Females - Numerator	Females - Denominator	Males (<25) - Numerator	Males (<25) - Denominator	Females (<25) - Numerator	Females (<25) - Denominator

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Year of survey	Sample size	Percentage (%)	Numerator	Denominator

b) Men who have sex with men

Is topic relevant?: Yes

Case definition:

Number of sites:

Information about the sites:

Sampling method:

Are the data representative of the entire country?:

2.5 Men who have sex with men: condom use

is indicator/topic relevant?: Yes
Are new data available? (Please do not repeat data that was reported in a prior year): No
Data measurement tool / source:
Other measurement tool / source:
From date:
To date:
Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents:

	All	<25	25+
Percentage (%) : Percentage of men reporting use of a condom the last time they had anal sex with a male partner			
Numerator : Number of men who have sex with men who reported that a condom was used the last time they had anal sex with a male partner			
Denominator : Number of men who have sex with men who reported having had anal sex with a male partner in the past six months			

Sub-national data

Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Year of survey	Sample size	Percentage (%)	Numerator	Denominator

2.6 HIV testing in men who have sex with men

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents:

	All	<25	25+
Percentage (%) : Percentage of men who have sex with men who received an HIV test in the past 12 months and know their results			
Numerator : Number of men who have sex with men who have been tested for HIV during the past 12 months and who know their results			
Denominator : Number of men who have sex with men included in the sample			

Sub-national data

Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Year of survey	Sample size	Percentage (%)	Numerator	Denominator

2.7 HIV prevalence in men who have sex with men

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents:

	All	<25	25+
Percentage (%) : Percentage of men who have sex with men who are living with HIV			
Numerator : Number of men who have sex with men who test positive for HIV			
Denominator : Number of men who have sex with men tested for HIV			

Sub-national data

Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Year of survey	Sample size	Percentage (%)	Numerator	Denominator

c) People who inject drugs

Is topic relevant?: Yes

Case definition: Not easily traceable in Uganda

Number of sites:

Information about the sites: NO

Sampling method:

Are the data representative of the entire country?: No

2.8 Needles and syringes per person who inject drugs

is indicator/topic relevant?: Yes
Are new data available? (Please do not repeat data that was reported in a prior year): No
Data measurement tool / source:
Other measurement tool / source:
From date:
To date:
Additional information related to entered data. e.g. reference to primary data source, methodological concerns::
Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Total
Proportion (%) : Number of needles and syringes distributed per person who injects drugs per year by needle and syringe programmes	
Numerator : Number of needles and syringes distributed in the past 12 months by NSPs	
Denominator : Number of people who inject drugs in the country	

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Year of data collection	Number of needles distributed per person per year	Numerator	Denominator

2.9 People who inject drugs: condom use

is indicator/topic relevant?: Yes
Are new data available? (Please do not repeat data that was reported in a prior year): No
Data measurement tool / source:
Other measurement tool / source:
From date:
To date:
Additional information related to entered data. e.g. reference to primary data source, methodological concerns::
Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:: Condom services are provided to IDUs as part of general public

Sample size - Number of Survey Respondents:

	All	Males	Females	Transgender	<25	25+
Percentage (%) : Percentage of people who inject drugs reporting the use of a condom the last time they had sexual intercourse						
Numerator : Number of people who inject drugs who reported that a condom was used the last time they had sex						
Denominator : Number of people who inject drugs who report having injected drugs and having had sexual intercourse in the past month						

Sub-national data

Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator

Disaggregated by sex

Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]

Site	Males - Numerator	Males - Denominator	Females - Numerator	Females - Denominator	Males (<25) - Numerator	Males (<25) - Denominator	Females (<25) - Numerator	Females (<25) - Denominator

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Year of survey	Sample size	Percentage (%)	Numerator	Denominator

2.10 People who inject drugs: safe injecting practices

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents:

	All	Males	Females	Transgender	<25	25+
Percentage (%) : Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected						
Numerator : Number of people who inject drugs who report using sterile injecting equipment the last time they injected drugs						
Denominator : Number of people who inject drugs who report injecting drugs in the past month						

Sub-national data

Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator

Disaggregated by sex

Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]

Site	Males - Numerator	Males - Denominator	Females - Numerator	Females - Denominator	Males (<25) - Numerator	Males (<25) - Denominator	Females (<25) - Numerator	Females (<25) - Denominator

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Year of survey	Sample size	Percentage (%)	Numerator	Denominator

2.11 HIV testing in people who inject drugs

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:: Data not availble for this indicator as services are provided as part of general population HTS

Sample size - Number of Survey Respondents:

	All	Males	Females	Transgender	<25	25+
Percentage (%) : Percentage of people who inject drugs who received an HIV test in the past 12 months and know their results						
Numerator : Number of people who inject drugs respondents who have been tested for HIV during the past 12 months and who know their results						
Denominator : Number of people who inject drugs included in the sample						

Sub-national data

Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator

Disaggregated by sex

Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]

Site	Males - Numerator	Males - Denominator	Females - Numerator	Females - Denominator	Males (<25) - Numerator	Males (<25) - Denominator	Females (<25) - Numerator	Females (<25) - Denominator

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Year of survey	Sample size	Percentage (%)	Numerator	Denominator

2.12 HIV prevalence in people who inject drugs

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:: Data for this indicator not avialable

Sample size - Number of Survey Respondents:

	All	Males	Females	Transgender	<25	25+
Percentage (%) : Percentage of people who inject drugs who are living with HIV						
Numerator : Number of people who inject drugs who test positive for HIV						
Denominator : Number of people who inject drugs tested for HIV						

Sub-national data

Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator

Disaggregated by sex

Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]

Site	Males - Numerator	Males - Denominator	Females - Numerator	Females - Denominator	Males (<25) - Numerator	Males (<25) - Denominator	Females (<25) - Numerator	Females (<25) - Denominator

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Year of survey	Sample size	Percentage (%)	Numerator	Denominator

2.13 Opioid substitution therapy coverage

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:: Data not available

	All	Males	Females	Transgender	<25	25+
Percentage (%) : Percentage of people who inject drugs receiving opioid substitution therapy (OST)						
Numerator : Number of people who inject drugs and are on OST at a specified date						
Denominator : Number of opioid-dependent people who inject drugs in the country						

Sub-national data

Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator

Disaggregated by sex

Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]

Site	Males - Numerator	Males - Denominator	Females - Numerator	Females - Denominator	Males (<25) - Numerator	Males (<25) - Denominator	Females (<25) - Numerator	Females (<25) - Denominator

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Year of data collection	Coverage (%)	Numerator	Denominator

d) Inmates/detainees

Is topic relevant?: Yes

Case definition: No survey conducted for inmates/detainees

Number of sites:

Information about the sites:

Are the data representative of the entire country?:

2.14 HIV prevalence in inmates/detainees

is indicator/topic relevant?: Yes
Are new data available? (Please do not repeat data that was reported in a prior year): No
Data measurement tool / source:
Other measurement tool / source:
From date:
To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	All	Males	Females	Transgender	<25	25+
Percentage (%) : Percentage of inmates/detainees who are living with HIV						
Numerator : Number of inmates/detainees who test positive for HIV						
Denominator : Number of inmates/detainees who tested for HIV						

Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator

Disaggregated by sex

Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]

Site	Males - Numerator	Males - Denominator	Females - Numerator	Females - Denominator	Males (<25) - Numerator	Males (<25) - Denominator	Females (<25) - Numerator	Females (<25) - Denominator

e) Transgender people

Is topic relevant?: Yes

Case definition:

Number of sites:

Information about the sites:

Sampling method:

Are the data representative of the entire country?: No

2.15 HIV prevalence in transgender people

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:: Data not available for this indicator

Sample size - Number of Survey Respondents:

	All	Transman	Transwoman	Other	<25	25+
Percentage (%) : Percentage of transgender people who are living with HIV						
Numerator : Number of transgender people who test positive for HIV						
Denominator : Number of transgender people tested for HIV						

Total and disaggregated by age

Please enter the breakdown per site below. [Add as many as needed]

Site	Sample size	Percentage (%)	All - Numerator	All - Denominator	<25 - Numerator	<25 - Denominator	25+ - Numerator	25+ - Denominator

Disaggregated by sex

Please enter the breakdown per site in the same order as in the table above. [Add as many as needed]

Site	Transmen - Numerator	Transmen - Denominator	Transwomen - Numerator	Transwomen - Denominator	Transmen (<25) - Numerator	Transmen (<25) - Denominator	Transwomen (<25) - Numerator	Transwomen (<25) - Denominator

3.1 Prevention of mother-to-child transmission

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Numerator from ANC/PMTCT registers only

Other measurement tool / source:

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Data value
Percentage (%) : Percentage of HIV-positive pregnant women who received antiretroviral medicine (ARV) to reduce the risk of mother-to-child transmission	
Numerator : Number of HIV-positive pregnant women who delivered and received ARVs during the past 12 months to reduce the risk of mother-to-child transmission during pregnancy and delivery.	117887
1. Newly initiated on antiretroviral therapy during the current pregnancy	47680
2. Already on antiretroviral therapy before the current pregnancy	70207
3. Maternal triple ARV prophylaxis (prophylaxis component of WHO Option B)	0
4. Maternal AZT (prophylaxis component during pregnancy and delivery of WHO Option A or WHO 2006 guidelines)	0
5. Single dose nevirapine (with or without tail) only **Please note that the final published value for PMTCT coverage will not include single dose nevirapine. However, this data is collected in the reporting tool during the phase out period.**	0
6. Other (please comment: e.g. specify regimen, uncategorized, etc.) **In the Comment Box, for the women reported as receiving an "Other" regimen, please describe the ARV regimen(s) and the number of women receiving each regimen category.**	0
If disaggregations 1 and 2 are not available, please provide the total number of pregnant women on Lifelong antiretroviral therapy	
Denominator : Estimated number of HIV-positive pregnant women who delivered within the past 12 months	

Take denominator from the final Spectrum file: Yes

For the women reported as receiving an "Other" regimen, please describe the ARV regimen(s) and the number of women receiving each regimen category.:

Sub-national data

Please enter the breakdown per region below. [Add as many as needed]

Sub-national region	Percentage (%)	Total number of HIV+ pregnant women who delivered and received ARV drugs	1. newly initiated on ART during the current pregnancy	2. already on ART before the current pregnancy	3. Maternal triple ARV prophylaxis (prophylaxis component of WHO Option B)	4. Maternal AZT (prophylaxis component during pregnancy and delivery of WHO Option A or WHO 2006 guidelines)	5. Single dose nevirapine (with or without tail) ONLY	6. Other	If disaggregations 1 and 2 are not available, please provide the total number of pregnant women on Lifelong ART	Denominator
Central 1		20085	6823	13262						
Central 2		14097	6875	7222						
East Central		5588	2342	3246						
Kampala		14415	5873	8542						
Mid-Eastern		7104	2705	4399						
Mid- Northern		17645	7623	10022						
Mid- Western		16674	7196	9478						
North East		5642	1617	4025						
South Western		12842	5053	7789						
West Nile		3795	1573	2222						

Alternatively, you may download this template, fill in the columns, and upload using the "Add File" button.

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Percentage (%)	Total number of HIV+ pregnant women who delivered and received ARV drugs	1. newly initiated on ART during the current pregnancy	2. already on ART before the current pregnancy	3. Maternal triple ARV prophylaxis (prophylaxis component of WHO Option B)	4. Maternal AZT (prophylaxis component during pregnancy and delivery of WHO Option A or WHO 2006 guidelines)	5. Single dose nevirapine (with or without tail) ONLY	6. Other	If disaggregations 1 and 2 are not available, please provide the total number of pregnant women on Lifelong ART	Denominator
KAmpala		14415	5873	8542						

3.2 Early infant diagnosis

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: EID Testing laboratories and sentinel surveillance

Other measurement tool / source:

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:: EID Jan to Dec 2015 Number of 1st DNA PCR tests 63,078 Number of positive 1st DBS 3016 Number of 2nd DNA PCR tests 33448 Number of positive 2nd DBS 871 Number of children receiving 1st DNA PCR by 2 months 40099 Number of positive results for 1st DNA PCR by 2 months 1457 Number of infants receiving a serological test at 18 months or older 27139 Number of infants testing positive on a serological test at 18 months or older 926 Note: It's not easy to know the total number of infants born to positive mothers as some are born out of the facility but 1st DNA gives an approximate number of only those captured by the facility. We can assume that total positives born in the years is the sum of all positives on each test i.e. : 3016+871+926=4813, This is however just an assumption because this number only shows those identified by the facility and does not include those that didn't come to the facility, this is best got from estimates again

	Data value
Percentage (%) : Percentage of infants born to HIV-positive women receiving a virological test for HIV within two months of birth	
Numerator : Number of infants who received an HIV test within two months of birth, during the reporting period. Infants tested should only be counted once	40099
Test result - Positive	1457
Test result - Negative	38642
Test result - Indeterminate	0
Test result - Rejected for testing	0
Test result - Other	0
Denominator : Number of HIV-positive pregnant women giving birth in the past 12 months	

Take denominator from the final Spectrum file: Yes

3.3 Mother-to-child transmission of HIV

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Spectrum

Other measurement tool / source:

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Data value
Percentage (%) : Estimated percentage of child HIV infections from HIV-positive women delivering in the past 12 months	
Numerator : Estimated number of children newly infected with HIV due to mother-to-child transmission among children born in the previous 12 months to HIV-positive women	9500
Denominator : Estimated number of HIV positive women who delivered in the previous 12 months	

Take data from the final Spectrum file: Yes

3.3a Programme-level mother-to-child transmission of HIV

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::
Don’t have a complete data set as most deliver out of the facility, better to use estimate

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Data value
Percentage (%) : Registered percentage of child HIV infections from HIV-positive women delivering in the past 12 months* *** Or a different period for which you have data. Please specify in the data collection period.**	
Numerator : Reported number of children born, in a defined year, to HIV-positive mothers, who were diagnosed as HIV positive.	
Denominator : Reported number of infants born to HIV-positive mothers within the defined year with a definitive diagnosis (sum of HIV-positive and HIV-negative).	

Additional information

	Data value
Children that were found to be HIV-negative	
Children that didn't receive a definitive diagnosis	
Total number of HIV exposed children during the calendar year	

3.4 PMTCT testing coverage

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Please specify

Other measurement tool / source: HMIS

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:: Number of pregnant women who attended an ANC or had a facility-based delivery in the past 12 months. Don’t have a complete data set as most deliver out of the facility, better to use estimate

	All pregnant women	Pregnant women who inject drugs (optional)
Percentage (%) : Percentage of pregnant women with known HIV status (based on population-based denominator)		
Numerator : Number of pregnant women attending antenatal clinics (ANC) and/or had a facility-based delivery and were tested for HIV during pregnancy, or already knew they were HIV positive	1758370	
1. known HIV infection at ANC entry	60190	
2. tested HIV positive at ANC during current pregnancy	45206	
3. tested HIV negative at ANC during current pregnancy	1630003	
Total identified HIV-positive women (sum of items 1 and 2)	105396	
Population-based denominator : Number of pregnant women who delivered within the past 12 months		
Facility-based denominator : Number of pregnant women who attended an ANC or had a facility-based delivery in the past 12 months		

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Percentage (using population-based denominator)	Numerator	Population-based denominator

3.5 Testing coverage of pregnant women's partners

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Please specify

Other measurement tool / source: HMIS

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns:: Information on "pregnant women attending ANC whose male partners were tested for HIV during pregnancy" was not captured by test result - negative/positive

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	All tested	Tested positive	Tested negative
Percentage (%) : Percentage of pregnant women attending ANC whose male partners were tested for HIV during pregnancy	25.02		
Numerator : Number of pregnant women attending ANC within the past 12 months whose male partners were tested or were already known to be HIV-positive	413825		
Denominator : Number of pregnant women attending ANC within the past 12 months	1654222		

3.7 Coverage of infant ARV prophylaxis

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Please specify

Other measurement tool / source: HMIS data set

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Data value
Percentage (%) : Percentage of HIV-exposed infants who initiated ARV prophylaxis (based on population-based denominator)	
Numerator : Number of HIV-exposed infants born within the past 12 months who were started on ARV prophylaxis at birth	45934
Population-based denominator : Number of HIV-positive women who delivered within the past 12 months	
Facility-based denominator : Number of HIV-positive women who delivered in a facility within the past 12 months	

Take population-based denominator from the final Spectrum file: Yes

3.9 Cotrimoxazole (CTX) prophylaxis coverage

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Please specify

Other measurement tool / source: HMIS data

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Data value
Percentage (%) : Percentage of HIV-exposed infants started on CTX prophylaxis within two months of birth	
Numerator : Number of HIV-exposed infants born within the past 12 months who started on CTX within two months of birth	45992
Denominator : Number of HIV-positive women who delivered within the past 12 months	

Take denominator from the final Spectrum file: Yes

4.1 HIV treatment: antiretroviral therapy

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Antiretroviral Therapy Patient Registers

Other measurement tool / source:

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:: Data on ART from HIMS is dis-agregated as follows, <2 years, 2-4yrs, 5-14yrs, 15+years, not dis-agregated new enrollment <2 yrs: 3,315 2-4yrs: 2,843 5-14yrs: 4,817 15yrs: 149,359 Not categorised: 133

Take denominators from the final Spectrum file: Yes

Total and disaggregated by sex

	Total	Males	Females	Gender unknown
Percentage (%) : Percentage of adults and children receiving antiretroviral therapy among all adults and children living with HIV				
Numerator : Number of adults and children receiving antiretroviral therapy at the end of the reporting period	834931	278300	556631	0
Denominator 1 : Estimated number of adults and children living with HIV **National criteria for ART eligibility varies by country. To make this indicator comparable across countries global reports will present the ART coverage for adults and children as a percent of all people living with HIV.**				
Denominator 2 : Estimated number of eligible adults and children (using national eligibility criteria)				
Number : Number of adults and children newly initiating antiretroviral therapy during the last reporting year	160467	55252	102630	2585

Disaggregated by broad age group

	<15	15+	Age unknown
Percentage (%) : Percentage of adults and children receiving antiretroviral therapy among all adults and children living with HIV **Percentage is based on Denominator 1.**			
Numerator : Number of adults and children receiving antiretroviral therapy at the end of the reporting period	60029	774902	0
Denominator 1 : Estimated number of adults and children living with HIV			
Denominator 2 : Estimated number of eligible adults and children (using national eligibility criteria) **National criteria for ART eligibility varies by country. To make this indicator comparable across countries, global reports will present the ART coverage for adults and children as a percent of all people living with HIV.**			
Number : Number of adults and children newly initiating antiretroviral therapy during the last reporting year	10975	149359	133

Disaggregated by detailed age group

	< 1	1-4	5-9	10-14	15-19	20-24	25-49	50+
Percentage (%) : Percentage of adults and children receiving antiretroviral therapy among all adults and children living with HIV **Percentage is based on Denominator 1.**								
Numerator : Number of adults and children receiving antiretroviral therapy at the end of the reporting period								
Denominator 1 : Estimated number of adults and children living with HIV								
Denominator 2 : Estimated number of eligible adults and children (using national eligibility criteria) **National criteria for ART eligibility varies by country. To make this indicator comparable across countries, global reports will present the ART coverage for adults and children as a percent of all people living with HIV.**								
Number : Number of adults and children newly initiating antiretroviral therapy during the last reporting year								

Disaggregated by sector

	Public sector	Private sector
Numerator : Number of adults and children receiving antiretroviral therapy at the end of the reporting period		

Sub-national data

Please enter the breakdown per region below. [Add as many as needed]

Sub-national region	All ages - Percentage	All ages - Numerator	All ages - Denominator 1	Children (<15) - Percentage	Children (<15) - Numerator	Children (<15) - Denominator 1	Adults (15+) - Percentage	Adults (15+) - Numerator	Adults (15+) - Denominator 1
Central 1		147986			9841			138145	
Central 2		84659			5965			78694	
East Central		56678			4094			52584	
Kampala		126933			8635			118298	
Mid Eastern		46569			3908			42661	
Mid Northern		100031			8862			91169	
Mid Western		87345			6254			81091	
North East		41214			3618			37596	
South Western		114643			6710			107933	
West Nile		28873			2142			26731	

Alternatively, you may download this template, fill in the columns, and upload using the "Add File" button.

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Percentage (%)	Numerator	Denominator 1
Kampala		126933	

4.2 Twelve-month retention on antiretroviral therapy

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Antiretroviral Therapy Patient Registers

Other measurement tool / source:

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Total	Males	Females	<15	15+	Pregnancy status at start of therapy	Breastfeeding status at start of therapy
Percentage (%) : Percentage of adults and children with HIV known to be on treatment 12 months after starting antiretroviral therapy	77.6	78.5	77.2	79.59	77.4		
Numerator : Number of adults and children who are still alive and on antiretroviral therapy at 12 months after initiating treatment in 2014	75027	24638	50389	6758	68269		
Denominator : Total number of adults and children initiating antiretroviral therapy in 2014, within the reporting period, including those who have died since starting antiretroviral therapy, those who have stopped treatment and those recorded as lost to follow-up at month 12	96655	31385	65270	8491	88164		

Additional information: In addition to 'alive and on ART', please report other outcomes at 12 months after initiating treatment

	Data value
Lost to follow-up	
Stopped Therapy	
Died	

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Percentage (%)	Numerator	Denominator

4.2a Twenty-four-month retention on antiretroviral therapy

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Antiretroviral Therapy Patient Registers

Other measurement tool / source:

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns:: Any additional outcome collected in here is lost (missed clinical appointments for less than 90days). And have added it herewith. May chose to add it the number alive

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:: Until end of September 2015, the cohort analysis report in the DHIS only collected 2 variables ie the Net current cohort and retention on ART as the only out come and for only a 12 month period of follow up. Hence for the

1st 2 quarters of 2015 this is the only outcome available at 12 months. For the last 2 quarters of 2015 the revised report form was uploaded onto the DHIS 2 platform and had all the treatment outcomes (Alive and on ART, stopped, Lost, LTFU, and Dead) and for all follow up periods up to 72 months. These additional outcomes are presented in 24 and 60 data needs. The dilemma is how to present the additional outcomes at 12 months given that they are only available for part of the year, furthermore the age disagreagation for the treatment outcomes is only available for the 1st part of the year. The revised report form only provides for all clients and then pregnant women but not age. For this reason, I have provided the 12 month retention with some age dis-aggregation based on the Jan to June report but have not not provided additional outcomes in the follow up period given that they were not available for the Net Current Cohort used to generate retention. 24 and 60 months outcomes could only be obtained from the revised report format released in the last half of the year hence I have provided these but limited bu lack of age disaggregation.

	Total	Males	Females	<15	15+
Percentage (%) : Percentage of adults and children with HIV known to be on treatment 24 months after starting antiretroviral therapy in 2013	71.9				
Numerator : Number of adults and children who are still alive and on antiretroviral therapy 24 months after initiating treatment in 2013	17593				
Denominator : Total number of adults and children who started antiretroviral therapy in 2013, or a specified period, who were expected to remain in treatment for 24 months within the 2015 reporting period, or 24 months after the specified initiation period. **Includes those who have died since starting antiretroviral therapy, those who have stopped the treatment and those recorded as lost to follow-up at month 24.**	24468				

Additional information: In addition to 'alive and on ART', please report other outcomes at 24 months after initiating treatment

	Data value
Lost to follow-up	5203
Stopped Therapy	56
Died	640

4.2b Sixty-month retention on antiretroviral therapy

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Antiretroviral Therapy Patient Registers

Other measurement tool / source:

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:: data avaible for only cohorts completing 60 months on treatment during the period July - December 2015 and data only available as total clientale and pregnant women

	Total	Males	Females	<15	15+
Percentage (%) : Percentage of adults and children with HIV known to be on treatment 60 months after starting antiretroviral therapy in 2010	70.8				
Numerator : Number of adults and children who are still alive and on antiretroviral therapy 60 months after initiating treatment in 2010	5729				
Denominator : Total number of adults and children who started antiretroviral therapy in 2010, or another specified period, who were expected to remain in treatment for 60 months within the 2015 reporting period, or 60 months after the specified initiation period. **Includes those who have died since starting antiretroviral therapy, those who have stopped treatment and those recorded as lost to follow-up at month 60**	8087				

Additional information: In addition to 'alive and on ART', please report other outcomes at 60 months after initiating treatment

	Data value
Lost to follow-up	1690
Stopped Therapy	14
Died	450

4.3 HIV care coverage

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Please specify

Other measurement tool / source: HMIS

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns:: The %age and denominator would seem like the numerator would go beyond only individuals enrolled in care in 2015 and would include the all those ever enrolled and still in care at the end of 2015- and this what I have provided. While Clients on ART are sufficiently disagregated, those on pre-ART are only disagregared into children and adults

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Total	Males	Females	<5	5-14	15+	Received care for the first time in the reporting year
Percentage (%) : Percentage of people currently receiving HIV care							
Numerator : Number of people enrolled in HIV care in 2015, as proxied by receipt of at least one of the following: clinical assessment (WHO staging); CD4 count; viral load; or currently receiving antiretroviral therapy.	945752				64880	880872	
Denominator : Estimated number of adults and children living with HIV							

Take denominator from the final Spectrum file: Yes

Disaggregation by mode of transmission (for European region only)

	People who inject drugs	Sex between men	Heterosexual contact	Mother-to-child transmission	Other and Unknown
Percentage (%) : Percentage of people currently receiving HIV care					
Numerator : Number of people enrolled in HIV care in 2015, as proxied by receipt of at least one of the following: clinical assessment (WHO staging); CD4 count; viral load; or currently receiving antiretroviral therapy.					
Denominator : Size estimate of key population					

4.4 Antiretroviral medicines (ARVs) stock-outs

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:: Data to be available in a weeks time

	Total	Community	Primary	Secondary	Tertiary
Percentage (%) : Percentage of facilities with stock-outs of antiretroviral drugs					
Numerator : Number of health facilities dispensing ARVs that experienced a stock-out of one or more required ARV medicines in the past 12 months					
Denominator : Total number of health facilities dispensing ARVs					

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Percentage (%)	Numerator	Denominator

4.5 Late HIV diagnoses

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:: Data to be available in a weeks time

	All	Males	Females	<15	15+
Percentage (%) : Percentage of HIV positive persons with first CD4 cell count < 200 cells/µL in 2015					
Numerator : Number of HIV-positive people with first CD4 cell count <200 cells/µl in 2015					
Denominator : Total number of HIV-positive people with first CD4 cell count in 2015					

4.6 Viral load suppression

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

I. <u>Routine programme data</u>

Total and disaggregated by sex

	Total	Males	Females	Gender unknown
Percentage (%) : Percentage of adults and children receiving antiretroviral therapy who were virally suppressed in the reporting period (2015)				
Numerator : Number of adults and children receiving antiretroviral therapy in the reporting period with suppressed viral load (i.e. ≤1000 copies)				
Number tested : Number of people tested for viral suppression during the last reporting year				
Denominator : Number of adults and children currently receiving antiretroviral therapy (taken from GARPR 4.1, no need to fill in)	834931	278300	556631	0

Disaggregated by broad age group

	<15	15+	Age unknown
Percentage (%) : Percentage of adults and children receiving antiretroviral therapy who were virally suppressed in the reporting period (2015)			
Numerator : Number of adults and children receiving antiretroviral therapy in the reporting period with suppressed viral load (i.e. ≤1000 copies)			
Number tested : Number of people tested for viral suppression during the last reporting year			
Denominator : Number of adults and children currently receiving antiretroviral therapy (taken from GARPR 4.1, no need to fill in)	60029	774902	0

Disaggregated by detailed age group

	< 1	1-4	5-9	10-14	15-19	20-24	25-49	50+
Percentage (%) : Percentage of adults and children receiving antiretroviral therapy who were virally suppressed in the reporting period (2015)								
Numerator : Number of adults and children receiving antiretroviral therapy in the reporting period with suppressed viral load (i.e. ≤1000 copies)								
Number tested : Number of people tested for viral suppression during the last reporting year								
Denominator : Number of adults and children currently receiving antiretroviral therapy (taken from GARPR 4.1, no need to fill in)								

II. Survey data

Total and disaggregated by sex

	Total	Males	Females
Percentage (%) : Percentage of adults and children receiving antiretroviral therapy who were virally suppressed in the reporting period (2015)			
Numerator : Number of adults and children receiving antiretroviral therapy in the reporting period with suppressed viral load (i.e. ≤1000 copies)			
Denominator : Number of adults and children currently receiving antiretroviral therapy			
Sample size : Number of Survey Respondents			

Disaggregated by broad age group

	<15	15+
Percentage (%) : Percentage of adults and children receiving antiretroviral therapy who were virally suppressed in the reporting period (2015)		
Numerator : Number of adults and children receiving antiretroviral therapy in the reporting period with suppressed viral load (i.e. ≤1000 copies)		
Denominator : Number of adults and children currently receiving antiretroviral therapy		
Sample size : Number of Survey Respondents		

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Percentage from Routine programme data	Numerator	Number tested	Denominator

4.7 AIDS-related deaths

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Please specify

Other measurement tool / source: Data to be obtained from Spectrum file

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Take data from the final Spectrum file: Yes

Total number who have died of AIDS-related illness in 2015

	Total	Males	Females	Gender unknown
All ages	27042			
<5 years				
5-14 years				
15+ years				

Sub-national data

Please enter the breakdown per region below. [Add as many as needed]

Sub-national region	Total	Males	Females	Males - <5 years	Males - 5-14 years	Males - 15+ years	Females - <5 years	Females - 5-14 years	Females - 15+ years

Alternatively, you may download this template, fill in the columns, and upload using the "Add File" button.

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Total number of AIDS-deaths

6.1 AIDS spending

Background information

Are you submitting expenditure data in this reporting cycle?: No

If yes, for which years are you submitting expenditure information?:

if other, please specify:

Steps to submit AIDS Funding Matrix

Dear country rapporteurs,

To report on Indicator 6.1 AIDS Spending, please complete the following steps:

1. Download an empty National Funding Matrix:

GARPR_6-1_en.xlsx

2. Fill-in the National Funding Matrix, and send the final form to aidsspending@unaids.org

3. We will review and revert in case there are any further queries, and will appreciate your prompt response.

For any questions about National Funding Matrix submissions, please contact aidsspending@unaids.org

Regards,
GARPR team

7.1 Prevalence of recent intimate partner violence

is indicator/topic relevant?: Yes
Are new data available? (Please do not repeat data that was reported in a prior year): No
Data measurement tool / source:
Other measurement tool / source:
From date:
To date:
Additional information related to entered data. e.g. reference to primary data source, methodological concerns::
Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents:

	Females (all ages)	HIV+ Females	HIV- Females	Females with unknown HIV status	Females (15-19)	HIV+ Females (15-19)	HIV- Females (15-19)	Females with unknown HIV status (15-19)	Females (20-24)	HIV+ Females (20-24)	HIV- Females (20-24)	Females with unknown HIV status (20-24)	Females (25-49)	HIV+ Females (25-49)	HIV- Females (25-49)	Females with unknown HIV status (25-49)
Percentage (%) : Proportion of ever married or partnered women aged 15–49 who experienced physical or sexual violence from a male intimate partner in the past 12 months																
Numerator : Women aged 15–49 who have or have ever had an intimate partner, who report experiencing physical or sexual violence by at least one of these partners in the past 12 months.																
Denominator : Total women surveyed aged 15–49 who currently have or have had an intimate partner																

If data is available on gender-based violence towards key populations, kindly include this data in the comment box below. Please upload any relevant reports using the "Add File" button at the top of this page.:

8.1 Discriminatory attitudes towards people living with HIV

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Sample size - Number of Survey Respondents:

Answered "No" to question 1 "Would you buy fresh vegetables from a shopkeeper or vendor if you knew that this person had HIV?"

	All ages	Males (15-49)	Males (15-19)	Males (20-24)	Males (25-49)	Females (15-49)	Females (15-19)	Females (20-24)	Females (25-49)
Percentage (%) : Percentage of respondents (aged 15–49 years) who respond “No” to question 1									
Numerator : Number of respondents (aged 15–49 years) who respond “No” to question 1									
Denominator : Number of all respondents aged 15–49 years who have heard of HIV									
Responded "Don't know", "Not Sure", or "It depends" : Number of all respondents aged 15–49 years who responded "don't know", "not sure", or "it depends" to question 1									

Data measurement tool/source for Question 2 (if different from the measurement source indicated above):

If data measurement tool/source for Question 2 is "Other", please specify:

Answered "No" to question 2 "Do you think children living with HIV should be able to attend school with children who are HIV negative?"

	All ages	Males (15-49)	Males (15-19)	Males (20-24)	Males (25-49)	Females (15-49)	Females (15-19)	Females (20-24)	Females (25-49)
Percentage (%) : Percentage of respondents (aged 15–49 years) who respond “No” to question 2									
Numerator : Number of respondents (aged 15–49 years) who respond “No” to question 2									
Denominator : Number of all respondents aged 15–49 years who have heard of HIV									
Responded "Don't know", "Not Sure", or "It depends" : Number of all respondents aged 15–49 years who responded "don't know", "not sure", or "it depends" to question 2									

Answered "No" to either question

	All ages	Males (15-49)	Males (15-19)	Males (20-24)	Males (25-49)	Females (15-49)	Females (15-19)	Females (20-24)	Females (25-49)
Percentage (%) : Percentage of respondents (aged 15–49 years) who respond “No” to either of the two questions									
Numerator : Number of respondents (aged 15–49 years) who respond “No” to either of the two questions									
Denominator : Number of all respondents aged 15–49 years who have heard of HIV									

10.2 External economic support to the poorest households

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Data value
Percentage (%) : Proportion of the poorest households who received external economic support in the last three months	
Numerator : Number of the poorest households that received any form of external economic support in the last three months **External economic support is defined as free economic help (cash transfers, assistance for school fees, material support for education, income generation support in cash or kind, food assistance provided at the household level, material or financial support for shelter, or other forms of economic support) that comes from a source other than friends, family or neighbours unless they are working for a community-based group or organization. This source is most likely to be the national government or a civil society organization.**	
Denominator : Total number of poorest households **Poorest households are defined as a household in the bottom wealth quintile. Countries should use the exact indicator definition and method of measurement for standardized progress monitoring and reporting at national and global levels. This will allow monitoring of changes over time and comparisons across different countries. However, countries can add or exclude other categories locally (for example, other wealth quintiles) depending on the country needs with respect to national programme planning and implementation**	

11.1 Co-management of tuberculosis and HIV treatment

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: Tuberculosis Patient Registers and Estimates from WHO Global TB database

Other measurement tool / source:

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Total	Males	Females	<15	15+
Numerator : Number of adults and children with HIV infection who received antiretroviral combination therapy in accordance with the nationally approved treatment protocol (or WHO/UNAIDS standards) and who were started on TB treatment (in accordance with national TB programme guidelines), within the reporting year	15448	9727	5721		

Note: WHO calculates annual estimates of the number of incident TB cases in people living with HIV. The 2015 denominator estimates, provided by countries on notification and antiretroviral therapy coverage, become available only in August of the reporting year and do not need to be provided at the time of reporting. The estimate for 2014 can be found at: http://www.who.int/tb/country/data/download/en/

City-specific data

Please provide information for the capital city of the country as well as one or two other key cities of high epidemiological relevance.

City	Total number who received ARV combination therapy

11.2 Proportion of people living with HIV newly enrolled in HIV care with active tuberculosis (TB) disease

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:: Data to be available in a weeks time

	Data value
Percentage (%) : Total number of people living with HIV having active TB expressed as a percentage of those who are newly enrolled in HIV care (pre-antiretroviral therapy or antiretroviral therapy) during the reporting period	
Numerator : Total number of persons who have active TB disease during the reporting period out of those newly enrolled in HIV care	
Denominator : Total number of persons newly enrolled in HIV care during the reporting period (pre-antiretroviral therapy plus antiretroviral therapy) **This denominator should be the same as the denominator of indicator 11.3**	

11.3 Proportion of people living with HIV newly enrolled in HIV care started on tuberculosis (TB) preventive therapy

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source:: Data to be available in a weeks time

	Data value
Percentage (%) : Number of patients started on treatment for latent TB infection, expressed as a percentage of the total number newly enrolled in HIV care during the reporting period	
Numerator : Total number of people living with HIV newly enrolled in HIV care who are started on treatment for latent TB infection during the reporting period	
Denominator : Total number of people newly enrolled in HIV care; that is, registered for pre-antiretroviral therapy or antiretroviral therapy during the reporting period **This denominator should be the same as the denominator of indicator 11.2**	

11.4 Hepatitis B testing

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Total	Males	Females	<15	15+	People who inject drugs
Percentage (%) : Proportion of people in HIV care who were tested for hepatitis B						
Numerator : Number of people in HIV care who were tested for hepatitis B during the reporting period using HBsAg tests						
Denominator : Number of people in HIV care during the reporting period						

11.5 Proportion of HIV-HBV co-infected persons currently on combined treatment

is indicator/topic relevant?: No

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Total	People who inject drugs
Percentage (%) : Proportion of HIV-HBV co-infected persons currently on combined treatment		
Numerator : Number of HIV/HBV coinfected people who receive treatment with ARVs effective against both viruses during the reporting period		
Denominator : Number of people diagnosed with HIV/HBV coinfection in HIV care during a reporting period (12 months)		

11.6 Hepatitis C testing

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Total	Males	Females	<15	15+	People who inject drugs
Percentage (%) : Proportion of people in HIV care who were tested for hepatitis C virus (HCV)						
Numerator : Number of adults and children in HIV care who were tested for hepatitis C during the reporting period using anti-HCV antibody tests						
Denominator : Number of adults and children in HIV care during the reporting period						

11.7 Proportion of persons diagnosed with HIV-HCV infection started on HCV treatment during a specified time frame (e.g. 12 months)

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

	Total	People who inject drugs
Percentage (%) : Proportion of people diagnosed with HIV/HCV coinfection started on treatment for HCV during a specified time frame (e.g. 12 months)		
Numerator : Number of people diagnosed with HIV/HCV coinfection started on treatment for HCV during a specified time frame (e.g. 12 months)		
Denominator : Number of people diagnosed with HIV/HCV coinfection in HIV care during a specified time period (12 months)		

11.8 Syphilis testing in pregnant women

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: National programme data

Other measurement tool / source:

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Are the data representative of the entire country?: Yes

If no, please describe:

At first visit

	Total
Percentage (%) : Percentage of women accessing antenatal care services who were tested for syphilis at first visit	14.05
Numerator : Number of women attending antenatal care services who were tested for syphilis at first visit	460763
Denominator : Number of women attending antenatal care services	3278999

At any visit

	Total
Percentage (%) : Percentage of pregnant women accessing antenatal care services who were tested for syphilis at any visit	
Numerator : Number of women attending antenatal care services who were tested for syphilis at any visit	
Denominator : Number of women attending antenatal care services	

11.9 Syphilis rates among antenatal care attendees

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: National programme data

Other measurement tool / source: Data not dis aggegated by age

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Are the data representative of the entire country?: Yes

If no, please describe:

Test type(s) generally used in your country to define positivity in pregnant women:: non-treponemal (RPR,VDRL),treponemal (rapid tests, TPPA),patients positive on both

	All	15-24	25+
Percentage (%) : Percentage of antenatal care attendees who were positive for syphilis	6.4		
Numerator : Number of antenatal care attendees who tested positive for syphilis	29605		
Denominator : Number of antenatal care attendees who were tested for syphilis	460763		

11.10 Syphilis treatment coverage among syphilis positive antenatal care attendees

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Are the data representative of the entire country?:

If no, please describe:

	Total
Percentage (%) : Percentage of antenatal care attendees positive for syphilis who received treatment	
Numerator : Number of antenatal care attendees with a positive syphilis serology who received at least one dose of benzathine penicillin 2.4 mU IM	
Denominator : Number of antenatal care attendees with a positive syphilis serology	

11.11 Congenital syphilis rate (live births and stillbirth)

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): No

Data measurement tool / source:

Other measurement tool / source:

From date:

To date:

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Are the data representative of the entire country?:

If no, please describe:

Does your case definition for congenital syphilis include stillbirths?:

Please comment on any major differences between the national case definition and the global surveillance case definition, available on page 15 of:
http://www.who.int/reproductivehealth/publications/rtis/9789241505895/en/index.html:

	Total
Percentage (%) : Percentage of reported congenital syphilis cases (live births and stillbirth)	
Numerator : Number of reported congenital syphilis cases (live births and stillbirths) in the past 12 months	
Denominator : Number of live births	

11.12 Men with urethral discharge

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: National case reporting

Other measurement tool / source:

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Are the data representative of the entire country?: Yes

If no, please describe:

	Total
Percentage (%) : Percentage of men reporting urethral discharge in the past 12 months	0.67
Numerator : Number of men reported with urethral discharge during the reporting period	35046
Denominator : Number of males aged 15 and older	5252896

11.13 Genital ulcer disease in adults

is indicator/topic relevant?: Yes

Are new data available? (Please do not repeat data that was reported in a prior year): Yes

Data measurement tool / source: National case reporting

Other measurement tool / source:

From date: 01/01/2015

To date: 31/12/2015

Additional information related to entered data. e.g. reference to primary data source, methodological concerns::
Data only dis-aggregated by 5 years upto 6o years

Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Are the data representative of the entire country?: Yes

If no, please describe:

	Total	Males	Females
Percentage (%) : Percentage of adults reported with genital ulcer disease in the past 12 months	1.4		
Numerator : Number of adults reported with genital ulcer disease during the reporting period	111596		
Denominator : Number of individuals aged 15 and older	7959592		

A HIV testing services

Is topic relevant?: Yes

If yes, please answer the questions below.

1) Populations. Do the current HIV testing services (HTS) guidelines address:

a) children: Yes

b) adolescents: Yes

c) key populations*: Yes

2) Provider-initiated HIV testing and counselling (PITC). Do the current HTS guidelines recommend PITC for:

a) all people attending health facilities: Yes

b) all pregnant women attending health facilities: Yes

c) all paediatric patients attending health facilities: Yes

d) all people with presumed or diagnosed tuberculosis (TB) infection attending health facilities: Yes

e) all people with presumed or diagnosed sexually transmitted infection (STI) attending health facilities: Yes

f) all people with presumed or diagnosed hepatitis (B/C) attending health facilities: Yes

g) all key populations attending health facilities: Yes

h) sexual partners of an HIV-positive person: Yes

i) other populations attending health facilities: Yes

If others, please specify: Fishermen, Uniformed personnel, Truckers

3) Do the current HTS guidelines recommend:

a) the use of community-based HTS:

b) the use of rapid diagnostic tests for community-based testing:

c) the use of rapid diagnostic tests in primary health care (PHC) settings: Yes

d) the use of rapid diagnostic tests for same day results for facility-based testing: Yes

e) the use of rapid diagnostic tests to be performed by lay providers*:

f) the use of rapid diagnostic tests for HIV self-testing: No

4) Couples/partner HTS. Do the current HTS guidelines recommend:

a) couples/partner HTS in all settings: Yes

b) couples/partner HTS in prevention of mother-to-child transmission (PMTCT) programmes: Yes

c) partner notification services in all settings:

B Antiretroviral Therapy

Is topic relevant?: Yes

If yes, please answer the questions below.

1) Status of antiretroviral (ARV) guidelines.

	Month and year of last completed and published version	Standalone or consolidated?
a) adult antiretroviral therapy guidelines	July,2014	Consolidated
b) PMTCT guidelines		Standalone
c) paediatric antiretroviral therapy guidelines	July, 2014	Consolidated
d) Operational/service delivery guidelines		

Please upload a copy of the document(s) if available

2) Have recommendations from WHO’s 2013 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection been adapted in a national process for:

a) adult antiretroviral therapy guidelines: Yes, completed

Please provide comment if you choose other:

b) PMTCT guidelines: Yes, completed

Please provide comment if you choose other:

c) paediatric antiretroviral therapy guidelines: Yes, completed

Please provide comment if you choose other:

3) Have recommendations from WHO’s 2015 Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection and early-release guidelines been adapted in a national process for:

a) adult antiretroviral therapy guidelines: On-going

Please provide comment if you choose other:

b) PMTCT guidelines: On-going

Please provide comment if you choose other:

c) paediatric antiretroviral therapy guidelines: On-going

Please provide comment if you choose other:

4) What are the national antiretroviral therapy targets for:

a) Total number of people on antiretroviral therapy (e.g. 1 million by 2015)

	Number	Year
adults (15+)	840,000	2015
children (<15)	54,000	2015

b) PMTCT antiretroviral therapy coverage among pregnant women* (e.g. XX% in 2016)

	Percentage	Year
1	95	2015
2		

5) What is the recommended CD4 threshold for initiating antiretroviral therapy in adults and adolescents who are asymptomatic:

a) as per Ministry of Health (MOH) guidelines or directive: ≤ 500

Please specify if you chose other :

b) what is the implementation status of the policy adopted above: : Done country-wide

Please provide comment if you choose other:

6) If national guidelines recommend a CD4 threshold of 500 or TREAT ALL, is prioritization given to persons with a CD4 <350 or to those with advanced clinical disease:: No

If yes, please specify:

Please provide comment if you choose other:

7) If your country has not yet adopted a TREAT ALL policy as per the WHO 2015 consolidated ARV guidelines, is there a plan to move towards adopting and implementing a TREAT ALL policy:: Yes

If yes, please include::

Planned year: 2016

Planned approach: Country-wide approach

If no, please provide feedback regarding challenges to adopting and implementing TREAT ALL:

8) Antiretroviral therapy initiation criteria adopted in national guidelines for infants and children with HIV:

a) what is the age cut-off to treat all children irrespective of symptoms as per MOH guidelines or directive: Other

Please provide comment if you choose other: less than 15 years

b) what is the implementation status of the age cut-off policy adopted in 8a): Done country-wide

Please provide comment if you choose other:

c) what is the CD4 cell count threshold in children aged five years and older who are asymptomatic per MOH guidelines or directive: TREAT ALL regardless of CD4 count

Please provide comment if you choose other:

d) what is the implementation status of the CD4 cell count threshold policy adopted above: Done country-wide

Please provide comment if you choose other:

9) Do national guidelines recommend antiretroviral therapy for all HIV-positive patients with active TB:: Yes

Please provide comment if you choose other:

10) Do national guidelines recommend antiretroviral therapy for all HIV-positive patients with hepatitis B, and severe liver disease:: Yes

Please provide comment if you choose other:

11) Do national guidelines recommend antiretroviral therapy for the HIV-positive partner in serodiscordant couples:: Yes

Please provide comment if you choose other:

12) Do national guidelines recommend treating HIV-positive persons identified as key populations* irrespective of CD4 cell count (TREAT ALL): : Yes

If yes, please specify the key population(s): MSM, CSWs, Fisher forks, Uniformed personnel, Truckers, Prisoners

13) For which population(s) is nurse-initiated antiretroviral therapy allowed : non-pregnant adults (men, women and transgender),pregnant women,adolescents (10-19 years old),children < 10 years old

Regimens

14) Is TDF/3TC or (FTC)/EFV the preferred first-line ARV combination for treatment initiation in national guidelines, among:

a) adults and adolescents: Yes

Please provide comment if you choose other:

b) pregnant women: Yes

Please provide comment if you choose other:

15) Does the country use fixed-dose antiretroviral therapy combinations as the preferred first-line therapy : Yes, 3 drug as one pill once a day

Please provide comment if you choose other:

16) Is there a policy to phase out D4T for:

a) adults and adolescents: Yes, fully phased out

Please provide comment if you choose other:

b) children: Yes, fully phased out

Please provide comment if you choose other:

17) Is AZT/3TC (or FTC)/ATV/r (or LPV/r) the preferred second-line ARV combination for adults and adolescents with HIV in the national guidelines:: Yes

Please provide comment if you choose other:

18) What is the preferred nucleoside reverse transcriptase inhibitor (NRTI) for treatment initiation in children aged less than three with HIV:: Abacavir (ABC)

Please specify if you chose other:

19) Are LPV/r based-regimens the preferred treatment option for all infants and children <36 months with HIV (irrespective of NNRTI exposure) in the national guidelines: : Yes, for all

20) Is efavirenz (EFV) recommended as the preferred NNRTI for treatment initiation in children aged three and older:: Yes

Please comment if you choose other :

21) What is the recommended NRTI backbone for treatment initiation in children aged 3–10 years:: ABC + 3TC (or FTC)

Please specify if you chose other:

22) What is the recommended NRTI backbone for treatment initiation in adolescents >35kg and at least 10 years of age:: TDF + 3TC (or FTC)

Please specify if you chose other:

Monitoring treatment response

23) Does the country use CD4 technology:

a) at the point of care: Yes

If yes, what proportion of facilities use point-of-care CD4 testing (%): 40

b) at the laboratory: Yes

c) both at the point of care and laboratory: Yes

d) if CD4 testing is available, what proportion of district hospitals have CD4 testing capacity? Provide an estimate (%): 100

e) what proportion of primary health-care facilities have access to CD4 cell count for testing their patients, whether on-site or nearby referral? Provide an estimate (%): 100

24) Is there a current national policy on routine viral load for monitoring antiretroviral therapy and what is the level of implementation:

a) for adults and adolescents: Yes, fully implemented

If Yes (fully or partially implemented), provide date: Partially implemented, and started around 2015

b) for children: Yes, fully implemented

If Yes (fully or partially implemented), provide date: Partially implemented, and started around 2015

25) What is the viral load testing policy/strategy for monitoring the treatment response:

a) for adults and adolescents:

i. routine first test at:: 6 months

ii. routine follow-up testing every:: 12 months

iii. targeted (based on suspected non-response to antiretroviral therapy): Yes

iv. other::

b) for children:

i. routine first test at:: 6 months

ii. routine follow-up testing every:: 6 months

iii. targeted (based on suspected non-response to antiretroviral therapy): No

iv. other::

26) Do you prioritize viral-load testing in select patient populations and situations:: Yes

if yes, please explain.: Prioritizing pregnant lactating women and children

27) What is the current availability and coverage of viral-load testing:

please specify X%: 100

a) at specialized centres only: Yes

b) all antiretroviral therapy facilities, either on-site or by referral: Yes

c) available at X% of antiretroviral therapy facilities: No

28) Do you have point-of-care viral load available in the country:: No

If yes, please explain how you are using point-of-care viral load in your strategy:

Service Delivery

29) Which of the following service provision modalities are included in the antiretroviral therapy national policy:

a) for adults and adolescents: antiretroviral therapy provision in TB clinics by TB providers,TB treatment in antiretroviral therapy settings by antiretroviral therapy providers,antiretroviral therapy provision in maternal, newborn and child health (MNCH) clinics by MNCH providers,antiretroviral therapy provision in primary health care (PHC) by PHC providers,mental health screening and treatment by antiretroviral therapy providers

If other, please specify :

b) for children: antiretroviral therapy provision in TB clinics by TB providers,TB treatment in antiretroviral therapy settings by antiretroviral therapy providers,antiretroviral therapy provision in maternal, newborn and child health (MNCH) clinics by MNCH providers,antiretroviral therapy provision in primary health care (PHC) by PHC providers,mental health screening and treatment by antiretroviral therapy providers

If other, please specify :

30) Which of the following coinfection policies are in place

a) for adults and adolescents: isoniazid preventive therapy (IPT) for people living with HIV (PLHIV),intensified TB case finding in PLHIV,TB infection control in HIV health-care settings,co-trimoxazole prophylaxis,hepatitis B screening in antiretroviral therapy clinics,hepatitis C screening in antiretroviral therapy clinics,hepatitis B management in antiretroviral

therapy clinics,hepatitis C management in antiretroviral therapy clinics,hepatitis B vaccination provided at antiretroviral therapy clinics,hepatitis C treatment provided in antiretroviral therapy clinics

If other, please specify :

b) for children: isoniazid preventive therapy (IPT) for PLHIV,intensified TB case finding in PLHIV,TB infection control in paediatric HIV health-care settings,co-trimoxazole prophylaxis,hepatitis B screening in antiretroviral therapy clinics,hepatitis C screening in antiretroviral therapy clinics,hepatitis B management in antiretroviral therapy clinics,hepatitis C management in antiretroviral therapy clinics,hepatitis B vaccination provided in antiretroviral therapy clinics,hepatitis C treatment provided in antiretroviral therapy clinics,sexual and reproductive health services (including STI and family planning) provided in antiretroviral therapy clinics

If other, please specify :

31) Are there national policies and strategies on linking HTC and enrolment into care:: Yes

If yes, do they include:

a) streamlined interventions (enhanced linkage, disclosure,tracing): Yes

b) peer support and patient navigation approaches: Yes

c) quality improvement approaches: Yes

d) CD4 at point of care : Yes

e) if others, please specify:

32) Are there national policies and strategies on retention in antiretroviral therapy:: Yes

If yes, do they include

a) community-based interventions: Yes

b) Adherence clubs and peer support: Yes

c) Extra care for high risk persons: Yes

if yes, please specify extra care for high risk persons: CSWs- with specific programmes that follow-up these groups

d) If others, please specify:

33) Are there national policies and strategies on adherence support:: Yes

If yes, do they include

a) peer counsellors: Yes

b) text messages: Yes

c) use of reminder devices: Yes

d) cognitive behavioural therapy: No

e) behavioural skills training/medication adherence training: Yes

f) fixed-dose combinations and once-daily regimens: Yes

g) if others, please specify:

34) Is there a national policy and strategy on community delivery of antiretroviral therapy:: Yes

If yes, specify what approaches are utilized to support community delivery of antiretroviral therapy: community models used by CSOs including delivery of ARVs, long intervals of replenishment

35) Is antiretroviral therapy provided in community settings (e.g. out of health-facility settings) and for stable patients on antiretroviral therapy:: Yes

If yes, is it implemented:: nationally

36) Is there a policy on differentiated care and prioritization of patients with advanced HIV disease:: No

37) Is there a national policy on frequency of clinic visit and ARV pick-up for stable patients on antiretroviral therapy:: Yes

If yes, please specify:: once a month clinic visit

38) Is there a national policy on frequency of ARV pick-up for stable patients on antiretroviral therapy:: Yes

If yes, please specify:: once a month ARV pick up

C Prevention of Mother-to-Child Transmission

Is topic relevant?: Yes

If yes, please answer the questions below.

1) Do you have a national plan for the elimination of mother-to-child transmission (MTCT) of HIV:: Yes

If yes, specify the MTCT transmission rate target(s) and year: 2013

If yes, specify the elimination target(s) (e.g. number of cases/pop) and year: 95% by 2015

2) Do you have a national plan for the elimination of MTCT of syphilis:: Yes, integrated with HIV or other elimination initiative(s)

3) Is there a national policy for routine screening of pregnant women for syphilis in your country:: Yes

If yes, what tests are used?:

a) laboratory-based non-treponemal (e.g. RPR/VDRL): Yes

b) laboratory-based treponemal (e.g. TPPA, TPHA): Yes

c) rapid syphilis treponemal tests (e.g. Bioline, Determine, Chembio) : Yes

d) dual HIV/syphilis rapid tests: Yes

4) What is the current nationally recommended PMTCT option, as per MOH guidelines or directive:: TREAT ALL (Option B+)

If Option B or TREAT ALL (Option B+), please specify since when: 2012

If TREAT ALL (Option B+), what is the practice in applying a TREAT ALL policy for HIV-positive pregnant and breastfeeding women: Done country-wide

Please provide comment if you choose other:

5) If currently implementing Option A or B, is transition to TREAT ALL planned:: No

If yes, in what year:

6) Are you conducting longitudinal cohort monitoring for pregnant women and infants:: Yes

If yes, at:

a) national level: Yes

b) subnational: Yes

c) select clinics (pilot or surveillance): Yes

Please provide details: Country adopted and has scaled up maternal and birth cohort monitoring country wide

7) What is the current nationally recommended first-line antiretroviral therapy regimen for pregnant and breastfeeding women with HIV:: TDF/3TC(FTC)/EFV

Please specify if you chose other:

8) What is the current nationally recommended PMTCT regimen for exposed infants:

Please specify the infant prophylaxis regimen : All exposed infants are given NVP upto six weeks

and the duration: six weeks

9) Is there a policy for dual prophylaxis in high-risk HIV-exposed infants (HEI):: No

If yes, what is the recommended regimen:

10) How is a high-risk exposure defined: Please specify:

11) Is nucleic acid testing for HIV (early infant diagnosis, DNA-PCR) at birth being introduced for HIV-exposed infants:: No

12) Is point-of-care nucleic acid testing for early infant diagnosis available in your country:: Yes

13) Are you conducting nine-month HIV antibody testing in HIV exposed infants:: No

14) Are you conducting a final diagnosis HIV antibody test at 18 months or three months post-cessation of breastfeeding:: Yes

15) Is there a national recommendation on infant feeding for HIV-exposed infants:: Yes, both recommended, left to individual choice or different settings

16) If breastfeeding is recommended for HIV-positive women and exposed infants, is the duration specified:: Yes

If Yes, please specify the duration in months: one year

D Sexually Transmitted Infections (STI)

Is topic relevant?: Yes

If yes, please answer the questions below.

1) Are there national STI treatment guidelines or recommendations: : Yes

If yes, year updated : 2010

2) Does your country have a national strategy or action plan for the prevention and control of STI:: Yes

3) Is gonococcal antimicrobial-resistance monitoring conducted in your country:: Yes, annually

4) Does the national definition for congenital syphilis include stillbirths:: Yes

E Key populations

Is topic relevant?: Yes

If yes, please answer the questions below.

1) Which of the following key populations or vulnerable groups are explicitly addressed in the national HIV policy or national plans:: Adolescent key populations,Men who have sex with men,People in prisons and other closed settings,Sex workers (male and female)

2) Do you have population-size estimates for the following populations:: Men who have sex with men,Sex workers (male and female)

3) People who inject drugs. Which of the following components of the comprehensive package of HIV prevention, diagnosis, treatment and care interventions for people who inject drugs are implemented in your country:

a) needle and syringe programmes (NSP): No

b.i) opioid substitution therapy (OST): No

b.ii) other drug dependence treatment: No

c) community provision of naloxone: No

d) HIV testing and counselling: No

e) antiretroviral therapy: No

f) sexually transmitted infection (STI) prevention and treatment: No

g) comprehensive condom programming: No

h) targeted information, education and communication (IEC): No

i) viral hepatitis prevention, diagnosis, treatment and vaccination: No

j) tuberculosis prevention, diagnosis and treatment: No

k) if other, please specify:

4) People in prisons and other closed settings. Which of the following components of the comprehensive package of HIV prevention, diagnosis, treatment and care interventions for key populations are implemented in your country:

a) comprehensive condom and lubricant programming: No

b) harm-reduction interventions for substance use:

NSP: No

OST: No

naloxone: No

c) behavioural interventions: Yes

d) HIV testing services: Yes

e) HIV treatment and care: Yes

f) coinfection and comorbidity (viral hepatitis, tuberculosis, mental health) prevention and management: Yes

g) sexual and reproductive health interventions: Yes

h) if other, please specify:

5) Sex workers. Which of the following components of the comprehensive package of HIV prevention, diagnosis, treatment and care interventions for key populations are implemented in your country:

a) comprehensive condom and lubricant programming: Yes

b) harm-reduction interventions for substance use:

NSP: No

OST: No

naloxone: No

c) behavioural interventions: Yes

d) HIV testing services: Yes

e) HIV treatment and care: Yes

f) coinfection and comorbidity (viral hepatitis, tuberculosis, mental health) prevention and management: Yes

g.i) symptomatic STI treatment: Yes

g.ii) screening for asymptomatic STI : Yes

g.iii) periodic presumptive STI treatment: No

h) if other, please specify:

6) Men who have sex with men. Which of the following components of the comprehensive package of HIV prevention, diagnosis, treatment and care interventions for key populations are implemented in your country:

a) comprehensive condom and lubricant programming: Yes

b) harm-reduction interventions for substance use:

NSP: No

OST: No

naloxone: No

c) behavioural interventions: Yes

d) HIV testing services: Yes

e) HIV treatment and care: Yes

f) pre-exposure prophylaxis (PrEP): No

g) coinfection and comorbidity (viral hepatitis, tuberculosis, mental health) prevention and management: Yes

h.i) symptomatic STI treatment: Yes

h.ii) screening for asymptomatic STI: Yes

i) if other, please specify:

7) Transgender people. Which of the following components of the comprehensive package of HIV prevention, diagnosis, treatment and care interventions for key populations are implemented in your country:

a) comprehensive condom and lubricant programming: No

b) harm-reduction interventions for substance use:

NSP: No

OST: No

naloxone: No

c) behavioural interventions: No

d) HIV testing services: No

e) HIV treatment and care: No

f) coinfection and comorbidity (viral hepatitis, tuberculosis, mental health) prevention and management: No

g.i) symptomatic STI treatment: No

g.ii) screening for asymptomatic STI: No

h) if other, please specify: No targeted services for transgender, however the national policy covers all categories of population

F Male circumcision

Is topic relevant?: No

If yes, please answer the questions below.

1) What is the target number for voluntary medical male circumcision, target age and current time frame:

target number of voluntary medical male circumcisions: 1000000

target age: 10-49years

target year: 2016

2) What is the status of operational planning and monitoring (multiple choices possible):

a) operational plan for 2016 exists: Yes

b) annual MC programme performance review conducted:

If yes, please specify in what year: In planning phase, apart from one done in 2014. Decision was to cover 2011 to 2013 and hence done in 2014 with a report available

c) MC HIV prevention programme is linked/has a working plan with adolescent health: Yes

d) MC technical working group/committee to review adverse events is established: Yes

3) What medical male circumcision methods are recommended/approved by the national programme:

a) conventional surgical methods (dorsal slit, forceps guided, sleeve resection): Yes

If yes, please specify any age disaggregations: Uganda first in South Africa, to introduce TWG to address the adverse effects and other issues around SMC. Two reports have been done and a publication

b) prequalified device method approved for use: Yes

If yes, please specify: Band (Prepex)

G PrEP and PEP

Is topic relevant?: Yes

If yes, please answer the questions below.

1) Is PreP provided in the country:: no

If yes, please specify for who :

2) Is PEP provided in the country:: Yes

If yes, please specify for who : Integrated in ART policy targeting Health workers, CSWs, sexually assaulted persons

3) What drugs are recommended for:

a) adults and adolescents: (please specify): TDF, 3TC, EFV

b) children: (please specify): TDF, 3TC, NPV

4) Number of prescriptions (for the reporting year)

a) adults/adolescents:

b) children:

5) Reason(s) for prescription (e.g. occupational, non-occupational etc): Please specify :

H Surveillance

Is topic relevant?: Yes

If yes, please answer the questions below.

1) Does the country carry out sentinel surveillance in the following special populations:

a) antenatal clinic attendees: Yes

if yes, please indicate:

Frequency in years: Annually until 2013

Number of sites: 56

Year of last survey: 2013

b)i. sex workers: No

if yes, please indicate:

Frequency in years:

Number of sites:

Year of last survey:

b)ii. people who inject drugs: No

if yes, please indicate:

Frequency in years:

Number of sites:

Year of last survey:

b)iii. men who have sex with men: No

if yes, please indicate:

Frequency in years:

Number of sites:

Year of last survey:

b)iv. transgender: No

if yes, please indicate:

Frequency in years:

Number of sites:

Year of last survey:

b)v. in prisons and other closed settings: No

if yes, please indicate:

Frequency in years:

Number of sites:

Year of last survey:

c) other specific populations: No

If yes, please specify the populations::

Frequency in years:

Number of sites:

Year of last survey:

I Monitoring and evaluation

Is topic relevant?: Yes

If yes, please answer the questions below.

1) What is the current status of planning for monitoring and evaluation (M&E) of the HIV and AIDS health-sector response:

a) national M&E plan exists: Yes

If yes, last updated in year : 2015

b) review of the M&E system was conducted: Yes

If yes, year of last review: 2014

c) review of the M&E system is planned: Yes

If yes, in year: 2018

J HIV Drug Resistance

Is topic relevant?: Yes

If yes, please answer the questions below.

1) In the past two years, has the country carried out HIV drug resistance (HIVDR) surveillance according to the following WHO protocols:

a) Pretreatment drug resistance surveys:

If yes, please specify year it was last started:

and number of clinics surveyed:

b) acquired drug resistance surveys among adults:

If yes, please specify year it was last started:

and number of clinics surveyed:

c) acquired drug resistance surveys among children:

If yes, please specify year it was last started:

and number of clinics surveyed:

d) infants (<18 months) drug resistance surveys using early infant diagnosis:

If yes, please specify year it was last started:

and number of clinics surveyed:

e) survey of clinic performance using early warning indicators for HIV drug resistance:

If yes, please specify year it was last started:

and number of clinics surveyed:

K Toxicity Monitoring Surveillance

Is topic relevant?: Yes

If yes, please answer the questions below.

1) Excluding passive pharmacovigilance approaches, is there an ongoing systematic effort to monitor the toxicity of ARVs in the country:: No

2) If yes, what approaches are used::

L Strategic planning and review

Is topic relevant?: Yes

If yes, please answer the questions below.

If applicable, please provide the dates for the following:

1) National and sub-national epidemiological analysis:

a) last epidemiological analysis conducted ([month]/[year]): Yes, 2014

b) next epidemiological analysis planned ([month]/[year]): 2016

2) Programmatic and financial gap analysis:

a) last programmatic and financial gap analysis conducted ([month]/[year]): 2014

b) next programmatic and financial gap analysis planned (Please specify [month]/[year]): 2017

3) What is the status of national HIV and AIDS programme development that includes HIV in the health sector:

a) HIV national (health sector) strategic plan is in place: Yes

If yes, specify validity: (from [year] to [year]): 2011/12- 2014/15

b) HIV (health sector) programme review was carried out: No

If yes, specify in which year:

c) next HIV (health sector) programme review is planned: Yes

If yes, specify for which year: 2016/2017

4) Does the national HIV (health sector) strategy address the following:: achieving universal access to antiretroviral therapy,collaboration between HIV and other services, including reproductive health,strengthening health systems,reducing inequities

M Reproductive Health and Research

Is topic relevant?: Yes

If yes, please answer the questions below.

1) Do you have service delivery points that provide the following appropriate medical and psychological care and support for women and men who have been raped and experienced incest, in accordance with the recommendations of WHO's 2013 guidelines, Responding to intimate partner violence and sexual violence against women:

a) first-line support or what is known as psychological first aid: Yes

b) emergency contraception to women who seek services within five days: Yes

c) safe abortion if a woman is pregnant as a result of rape, in accordance with national law: No

d) STI and HIV post-exposure prophylaxis (within 72 hours of sexual assault) as needed: Yes

0 Header

is indicator/topic relevant?: Yes
Are new data available? (Please do not repeat data that was reported in a prior year): No
Data measurement tool / source:
Other measurement tool / source:
From date:
To date:
Additional information related to entered data. e.g. reference to primary data source, methodological concerns::
Data related to this topic which does not fit into the indicator cells. Please specify methodology and reference to primary data source::

Survey to document the data situation in 2015

Name of person who filled in the questionnaire:

Position:

Institution:

E-mail address:

Phone:

1A ARV treatment overview (taken from GARPR 4.1 and 4.3; no need to fill in)

1B Treatment in HIV-infected adults and adolescents (10+ years old) including pregnant women

Question 1. Report the total number of HIV-infected adults and adolescents ≥10 years old by treatment line at the end of 2015

	Number of HIV-infected Adults and adolescents ≥10 years old receiving this regimen at end of December 2016
First Line	
Second Line	
Third Line	
TOTAL	

Question 2. Report the number of patients per 1st line ART regimens used in HIV-infected adults and adolescents ≥10 years old at end of 2015 including HIV-infected pregnant women who are on ART.

N.B. Please start by ART regimens with higher numbers by end 2015

List of 1st line ART regimens used in HIV-infected adults and adolescents ≥10 years old regimen at the end of 2015	Number of HIV-infected adults and adolescents ≥10 years old receiving this ART regimen at the end of 2015

Question 3. Report the number of patients per second line ART regimens used in HIV-infected adults and adolescents ≥10 years old at the end of 2015

N.B. Please start by ART regimens with higher numbers by end 2015

List of 2nd line ART regimens used in HIV-infected adults and adolescents ≥10 years old regimen at the end of 2015	Number of HIV-infected adults and adolescents ≥10 years old receiving this ART regimen at the end of 2015

Question 4 Report the number of patients per third line ART regimens used in HIV-infected adults and adolescents ≥10 years old at end of 2015

N.B. Please start by ART regimens with higher numbers by end 2015

List of 3rd line ART regimens used in HIV-infected adults and adolescents ≥10 years old at the end of 2015	Number of HIV-infected adults and adolescents ≥10 years old receiving this ART regimen at the end of 2015

2 Treatment in HIV-infected children (<10 years old)

Question 5. Number of HIV-infected children<10 years old by treatment line at the end of 2015.

	Number of HIV-infected children <10 years old receiving this regimen at the end of 2016
First Line	
Second Line	
Third Line	
TOTAL	

Question 6. Report the number of children per 1st line ART regimens used in HIV-infected infants and children <10 years old at the end of 2015

N.B. Please start by ART regimens with higher numbers by end 2015

List of 1st line regimens used in HIV-infected children at the end of 2015	# children < 3 years old receiving this regimen (A)	# children ≥3 to <10 years old receiving this regimen (B)	Total # children <10 years old receiving this regimen (A) + (B)

TOTAL

	No. of children < 3 years old receiving this regimen (A)	No. of children ≥3 to <10 years old receiving this regimen (B)	Total # children <10 years old receiving this regimen (A) + (B)
TOTAL			

Question 7: Report the number of children per second line ART regimen used in HIV-infected children <10 years old at the end of 2015

N.B. Please start by ART regimens with higher numbers by end 2015

List of 2nd line ART regimen used in HIV-infected children <10 years old at the end of 2015	Number of HIV-infected children <10 years old receiving this regimen at the end of 2015

Question 8: Report the number of children per third line ART regimen used in HIV-infected children <10 years old at the end of 2015

N.B. Please start by ART regimens with higher numbers by end 2015

List of 3rd line ART regimen used in HIV-infected children <10 years old at the end of 2015	Number of HIV-infected children <10 years old receiving this regimen at the end of 2015

3 Prevention of mother-to-child transmission

Question 9: Number and % of pregnant women who started antiretrovirals to reduce the risk of mother to child transmission and various PMTCT options during 2015 {GARPR 3.1}

Question 10 : What is the recommended PMTCT option for HIV-infected pregnant women in your country::

Please specify if you chose other:

Question 11. Report the number of pregnant women per ARV regimens used in your country for PMTCT Option A in 2015

N.B. Please start by ARV regimens with higher numbers by end 2015

Option A ART regimens used for HIV-infected pregnant women in 2015	Number of HIV-infected pregnant women who started this regimen in 2015

	Data value
TOTAL	

Question 12. Report the number of pregnant women per ARV regimens used in your country for PMTCT Option B in 2015

N.B. Please start by ARV regimens with higher numbers by end 2015

Option B ART regimens used for HIV-infected pregnant women in 2015	Number of HIV-infected pregnant women who started this regimen in 2015

	Data value
TOTAL	

Question 13. Report the number of pregnant women per ARV regimens used in your country for PMTCT Option B+ (Treat All) in 2015

N.B. Please start by ART regimens with higher numbers by end 2015

Option B+ ART regimens used for HIV-infected pregnant women in 2015	Number of HIV-infected pregnant women who started this regimen in 2015

	Data value
TOTAL	

Question 14. Report the number of neonates per ARV used in your country for HIV prophylaxis in neonates born from HIV-infected pregnant women in 2015

ARVs used for HIV prophylaxis of neonates born from HIV-infected mothers in 2015	Number of neonates started this regimen in 2015

	Data value
TOTAL	

4 Laboratory services

HIV tests

	Data value
Question 15. Total number of HIV tests (RDTs & ELISA) done between Jan- Dec 2015 : (Number of people tested for HIV: see GARP)	

CD4 Tests

	Data value
Question 16. Total number of CD4 tests done between Jan- Dec 2015	
Question 17. Total number of HIV-infected people who had at least one CD4 test between Jan- Dec 2015	
Question 18. Total number of patients on ART who had at least one CD4 test between Jan- Dec 2015	
Question 19. Total number of HIV-infected pregnant women who had at least one CD4 test between Jan- Dec 2015	

Viral load

	Data value
Question 20. Total number of VL tests done between Jan- Dec 2015	
Question 21. Total number of all HIV-infected people who had at least one VL test between Jan- Dec 2015	
Question 22. Total number of patients on ART who had at least one VL test between Jan- Dec 2015	
Question 23. Total number of HIV-infected pregnant women who had at least one VL test between Jan- Dec 2015	

Early Infant Diagnosis (EID)

	Data value
Question 24. Total number of EID tests done between Jan- Dec 2015	
Question 25. Total number of infants (<12 months old) born to HIV-infected mother who had at least one EID test between Jan- Dec 2015	

Question 26. Report the total number of labs or sites by type of tests in your country

Type of laboratory tests

	Total number of labs or sites where samples are collected (sites with testing and sites without testing) by type of test	Total number of labs or sites where the actual testing is done by type of test	Total number of labs or sites where the actual testing is done that participate in an external quality assessment (EQA) scheme by type of test	Total number of labs or sites that need quality improvement activities based on most recent EQA exercise by type of test	List main activities required for quality improvement by type of test
HIV serology antibody testing including rapid test & ELISA					
Early Infant Diagnosis (EID)					
CD4 testing					
Viral load testing					
HIVDR genotype testing					
GeneXpert (TB test)					

Question 27. Availability of laboratory HIV technologies: Report the number of machines/assays by technology available in your country.

Type of Assay/machine

	Number of laboratory machines	Number of lab / health facilities (ART or PMTCT) where the lab machine is installed	Number of lab machines not in use	Number of machines not in use: No reagents	Number of machines not in use: Not installed	Number of machines not in use: Need repair	Number of machines not in use: No staff trained	Number of machines not in use: Decommissioned	Number of machines not in use: Other reasons	Number of equipment with a maintenance contractual service	Number of equipment serviced in 2016
CD4 Technologies											
Alere Pima Analyzer											
Apogee Auto40 Flow Cytometer											
BD FACSCalibur											
BD FACSCount											
BD FACSPresto™ Near Patient CD4 Counter											
Coulter Epics											
Millipore-Guava											
Partec CyFlow											
Partec miniPOC											
PointCare NOW											

Other CD4 Technologies

Type of machine	Total number of laboratory machines	Number of sites where the lab machine is installed	Total No. of lab machines not in use	Number of machines not in use: No reagents	Number of machines not in use: Not installed	Number of machines not in use: Need repair	Number of machines not in use: No staff trained	Number of machines not in use: Decommissioned	Number of machines not in use: Other reasons	Number of equipment with a maintenance service contract	Number of equipment serviced in 2015

If there are machines not in use because of other reasons, please specify the reasons and the number of machines:

Type of machine

	Number of laboratory machines	Number of lab / health facilities (ART or PMTCT) where the lab machine is installed	Number of lab machines not in use	Number of machines not in use: No reagents	Number of machines not in use: Not installed	Number of machines not in use: Need repair	Number of machines not in use: No staff trained	Number of machines not in use: Decommissioned	Number of machines not in use: Other reasons	Number of equipment with a maintenance contractual service	Number of equipment serviced in 2016
Viral Load Technologies											
Abbott RealTime HIV-1 assay (A) /manual/m2000rt											
Abbott RealTime HIV-1 assay (A) /m24/m2000rt											
Abbott RealTime HIV-1 assay (A) /m2000sp/m2000rt											
Abbott RealTime HIV-1 Qualitative assay (B) /manual/m2000rt											
Abbott RealTime HIV-1 Qualitative assay (B) /m2000sp/m2000rt											
COBAS AMPLICOR HIV-1 MONITOR Test (A) / Amplicor (Roche)											
Roche Amplicor HIV-1 DNA test (B) / Amplicor											
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 (A) / COBAS TaqMan 48 (Roche)											
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 (A) / COBAS TaqMan 96 (Roche)											
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Qualitative (B) / COBAS TaqMan 48 (Roche)											
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Qualitative (B) / COBAS TaqMan 96 (Roche)											
GENERIC HIV CHARGE VIRALE (A) / one NorDiag Arrow instrument											
GENERIC HIV CHARGE VIRALE (A) / two NorDiag Arrow instruments											
NucliSENSEasyQ HIV-1 (A) / NucliSens miniMAG / EasyQ® (bioMerieux)											
NucliSENSEasyQ HIV-1 (A) / NucliSens easyMAG / EasyQ® (bioMerieux)											

VERSANT HIV-1 RNA 1.0 Assay (kPCR) (A) / VERSANT® kPCR Molecular System (Siemens)											

(A) - Assay intended to be used for measuring levels of HIV-1 RNA (viral load)

(B) - Assay intended for qualitative detection of HIV-1 RNA and DNA in adult and pediatric (including younger than 18 months of age: EID) patients.

Other Virological testing technologies

Type of machine	Total number of laboratory machines	Number of sites where the lab machine is installed	Total No. of lab machines not in use	Number of machines not in use: No reagents	Number of machines not in use: Not installed	Number of machines not in use: Need repair	Number of machines not in use: No staff trained	Number of machines not in use: Decommissioned	Number of machines not in use: Other reasons	Number of equipment with a maintenance service contract	Number of equipment serviced in 2015

If there are machines not in use because of other reasons, please specify the reasons and the number of machines:

5 Country targets

Question 28. In the table below, report the national targets for ART, PMTCT and lab tests

Country target

	At the end of 2016	At the end of 2017	At the end of 2018	At the end of 2019	At the end of 2020	At the end of 2021
1. Number of adults and children to be on ART						
Subset 1.1: Number of adults and adolescents (≥10 years) to be on ART						
Subset 1.2: Number of children <10 years to be on ART						
Sub-subset 1.2.1: Number of children <5 years to be on ART						
Sub-subset 1.2.2: Number of children ≥ 5 to <10 years to be on ART						
2. Total Number of pregnant women who started ART for PMTCT						
Subset 2.1: Number of pregnant women on Option B+						
Subset 2.2: Number of pregnant women on Option B						
Subset 2.3: Number of pregnant women on Option A						
3. Total number of people who will be tested for HIV infection						
4. Total number of people who will have CD4 tested						
5. Total number of people who will have VL tests						
6. Total number of children (born from HIV infected women) who will have EID tests						
7. Total number of HIV serology tests						
8. Total number of CD4 tests						
9. Total number of VL tests						
10. Total number of EID tests						

